ATE374367T1 - Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind - Google Patents

Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind

Info

Publication number
ATE374367T1
ATE374367T1 AT04017375T AT04017375T ATE374367T1 AT E374367 T1 ATE374367 T1 AT E374367T1 AT 04017375 T AT04017375 T AT 04017375T AT 04017375 T AT04017375 T AT 04017375T AT E374367 T1 ATE374367 T1 AT E374367T1
Authority
AT
Austria
Prior art keywords
angiogenesis
diseases associated
cyanine dyes
diagnosing diseases
diagnosing
Prior art date
Application number
AT04017375T
Other languages
English (en)
Inventor
Michael Schirner
Kai Licha
Peter Hauff
Christin Perlitz
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE374367T1 publication Critical patent/ATE374367T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Eye Examination Apparatus (AREA)
  • Materials For Medical Uses (AREA)
  • Peptides Or Proteins (AREA)
AT04017375T 2004-07-22 2004-07-22 Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind ATE374367T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04017375A EP1619501B1 (de) 2004-07-22 2004-07-22 Verwendung von Cyanin-farbstoffen zur Diagnose von Krankheiten, welche mit Angiogenese assoziert sind

Publications (1)

Publication Number Publication Date
ATE374367T1 true ATE374367T1 (de) 2007-10-15

Family

ID=34925879

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04017375T ATE374367T1 (de) 2004-07-22 2004-07-22 Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind

Country Status (15)

Country Link
EP (3) EP1619501B1 (de)
JP (1) JP2008506747A (de)
KR (1) KR20070062973A (de)
CN (1) CN101022835A (de)
AR (1) AR050264A1 (de)
AT (1) ATE374367T1 (de)
AU (1) AU2005263638A1 (de)
CA (1) CA2573783A1 (de)
DE (1) DE602004009169D1 (de)
PA (1) PA8640201A1 (de)
PE (1) PE20060558A1 (de)
SV (1) SV2006002172A (de)
TW (1) TW200613733A (de)
UY (1) UY29029A1 (de)
WO (1) WO2006008179A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1679082A1 (de) * 2005-01-07 2006-07-12 Schering AG Benutzung von Cyaninfarbstoffen für die Diagnose von proliferierenden Krankheiten
EP1745739A3 (de) * 2005-07-14 2009-04-22 Bundesrepublik Deutschland, vertr. d.d. Bundes- ministerium f. Wirtschaft- und Technologie, dieses vertr. d.d. Präs. d. Phys.-Techn. Bundesanstalt Optische Darstellung von rheumatischer Arthritis
DE102007037008B4 (de) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnosesubstanz zur Anwendung in einem Verfahren zur Bestimmung der Aggressivität eines Prostatatumors
DE102007038730A1 (de) * 2007-08-16 2009-02-19 Carl Zeiss Meditec Ag Nachweis des menschlichen Vascular Endothelial Growth Factor
EP2223086B2 (de) * 2007-12-14 2016-06-01 Biotium Inc. Fluoreszenzverbindungen - markierungsfarbstoffe
WO2009103312A1 (en) * 2008-02-19 2009-08-27 Ludwig-Maximilians-Universität Ezrin, serpin b5, peroxiredoxin-2 and heat shock protein beta-1 as autoantigens for psoriasis and poststreptococcal diseases
CN101518528B (zh) * 2008-02-29 2014-02-26 史春梦 一组碳花青染料类的近红外荧光化合物的用途
JP2012517434A (ja) * 2009-02-06 2012-08-02 ザ ジェネラル ホスピタル コーポレイション 血管病変を治療する方法
CA2766861A1 (en) * 2009-07-09 2011-01-13 F. Hoffmann-La Roche Ag In vivo tumor vasculature imaging
US8658434B2 (en) 2009-10-28 2014-02-25 Biotium, Inc. Fluorescent pyrene compounds
GB0922014D0 (en) 2009-12-17 2010-02-03 Ge Healthcare Ltd Novel integrin binders
WO2014122228A1 (en) 2013-02-07 2014-08-14 Westfaelische Wilhelms-Universitaet Muenster Labelled compounds that bind to alpha-v-beta-3 integrin
JP6752582B2 (ja) * 2016-02-08 2020-09-09 キヤノン株式会社 光音響イメージング用造影剤
TWI617281B (zh) * 2017-01-12 2018-03-11 財團法人工業技術研究院 傷口狀態分析方法與系統
CN108410202A (zh) * 2018-02-12 2018-08-17 成都驷博生物科技有限公司 一种喹啉七甲川菁染料的制备方法
CN110201189B (zh) * 2019-06-03 2021-12-07 沈阳药科大学 白蛋白结合型近红外荧光染料-马来酰亚胺共轭物
CN112994990B (zh) * 2021-05-20 2021-07-30 蚂蚁金服（杭州）网络技术有限公司 一种环路检测方法、装置、电子设备与存储介质

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1144688A (en) * 1987-03-17 1988-09-15 Dana-Farber Cancer Institute, Inc. A pharmaceutical composition comprising cyanine dye
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
DE19947559A1 (de) * 1999-09-24 2001-04-19 Schering Ag Antikörper-Farbstoffkonjugate gegen Zielstrukturen der Angiogenese zur intraoperativen Tumorranddarstellung
US6180086B1 (en) * 2000-01-18 2001-01-30 Mallinckrodt Inc. Hydrophilic cyanine dyes
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
RU2352582C2 (ru) * 2002-01-03 2009-04-20 Шеринг Акциенгезельшафт Конъюгаты, содержащие антитело, специфическое для ed-в-домена фибронектина, и их применение для обнаружения и лечения опухолей
ES2337566T3 (es) * 2002-03-11 2010-04-27 Philogen S.P.A. Anticuerpos derivados de anti ed-b l19 y vasculatura tumoral objetivo.
CA2514131A1 (en) * 2003-01-24 2004-08-05 Schering Ag Hydrophilic, thiol-reactive cyanine dyes and conjugates thereof with biomolecules for fluorescence diagnosis
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
EP1679082A1 (de) * 2005-01-07 2006-07-12 Schering AG Benutzung von Cyaninfarbstoffen für die Diagnose von proliferierenden Krankheiten

Also Published As

Publication number Publication date
WO2006008179A2 (en) 2006-01-26
CN101022835A (zh) 2007-08-22
JP2008506747A (ja) 2008-03-06
DE602004009169D1 (de) 2007-11-08
UY29029A1 (es) 2005-12-30
KR20070062973A (ko) 2007-06-18
WO2006008179A3 (en) 2007-01-11
PA8640201A1 (es) 2006-07-03
AU2005263638A1 (en) 2006-01-26
EP1619501B1 (de) 2007-09-26
EP1784226A2 (de) 2007-05-16
EP1816475A1 (de) 2007-08-08
TW200613733A (en) 2006-05-01
AR050264A1 (es) 2006-10-11
SV2006002172A (es) 2006-02-15
EP1619501A1 (de) 2006-01-25
PE20060558A1 (es) 2006-07-26
CA2573783A1 (en) 2006-01-26

Similar Documents

Publication Publication Date Title
ATE374367T1 (de) Verwendung von cyanin-farbstoffen zur diagnose von krankheiten, welche mit angiogenese assoziert sind
DE602005002836D1 (de) Diagnoseverfahren für erkrankungen unter verwendung von copeptin
IL182499A0 (en) Use of cyanine dyes for the diagnosis of proliferative diseases
DE602006016589D1 (de) Neue markierungsstrategien für den empfindlichen nachweis von analyten
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
DE602005018377D1 (de) Untersuchungsapparat mit Ultraschallsonde, Ultraschalluntersuchungsgerät mit einer Ultraschallsonde
DE602006009684D1 (de) Zwischenwirbelimplantat für das lumbosakralgelenk
NO20053169D0 (no) Fremgangsmate for fremstilling av integrerte biosensorer.
SG118408A1 (en) Methods of monitoring the concentration of an analyte
ATE494289T1 (de) Substituierte pyrazolopyrimidine, ein verfahren zu ihrer herstellung und ihre verwendung als medizin
ATE526307T1 (de) Hydroxybiphenyl-carbonsäuren und derivate, verfahren zu deren herstellung und deren verwendung
DE602006003318D1 (de) Fahrzeug und steuerverfahren für das fahrzeug
DE602005014723D1 (de) Blutentnahmeset mit vergrössertem Innenvolumen
DE602006014352D1 (de) Kautschukzusammensetzung für Innenschicht und Reifen, der diese enthält
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
DE602005026422D1 (de) Herstellung von Kohlenwasserstoffen unter Verwendung von Titankatalysatoren
DE602006012456D1 (de) Kühlgerät, steuerverfahren für das kühlgerät und verfahren zur bestimmung von anomalien
ATE431930T1 (de) Ileitis-diagnosetest
DE602006021626D1 (de) 1,1-dioxo-thiomorpholinyl-indolyl-methanon-derivate zur verwendung als h3-modulatoren
DE602005007817D1 (de) Analyse-Verfahren unter Verwendung von abgeschwächter Totalreflektion
ATE384046T1 (de) Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet
DE502006002680D1 (de) Verfahren zur herstellung von feinteiligem c.i. pigment red 254
EP1870710A4 (de) Biomarker zur diagnose einer herzerkrankung sowie verwendung davon
DE602006016258D1 (de) 4h-1,2,4-triazin-5-on-derivate, ihre herstellung und ihre verwendung als alpha-7-nikotin-acetylcholin-rezeptoren
DE602005015623D1 (de) Ils mit flexiblem lokalem bereich, z.b. zur verwendung als innenausstattung für ein kraftfahrzeug

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties